Bioperfectus, one of the leading in-vitro diagnostics providers for infectious diseases, has partnered with FIND, the global alliance for diagnostics, to lift the COVID-19 self-testing capacity in low- and middle-income countries (LMICs).

Bioperfectus Nucleic Acid Extraction System SSNP-3000A arrived at Sierra Leone-China Friendship Biological Safety Laboratory (SLE-CHN Biosafety Lab) during the Chinese New Year Festival.

Aprovação de Mercado para o Autoteste de Covid-19 de Bioperfectus em Portugal

Approvazione di Bioperfectus autotest per l’antigene COVID-19 in Italia

Bioperfectus today solemnly announce that Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit (Self-test) has been entered in the electronic registry of the Agencia Española de Medicamentos y Productos Sanitarios (Spanish Agency for Medicines and Health Products, AEMPS).

Bioperfectus SARS-CoV-2 Antigen Self-Testing is now officially included in Austrian Certified SARS-CoV-2 Antigen Rapid Tests Listing.

The demand for rapid tests is expected to go up after the government announced that the mandatory quarantine period for Israelis infected with COVID-19 would be shortened from a week to five days on January 17th, 2022.

Cervical cancer starts in the cells lining the cervix -- the lower part of the uterus (womb). The cervix connects the body of the uterus (the upper part where a fetus grows) to the vagina (birth canal).

2021 has been an exceptional year for Bioperfectus. We have successfully achieved many milestones by supplying our molecular diagnostic products to where people need them most. The glorious stories and moments shaped 2021 of Bioperfectus, now come and follow us for our special #2021Review.

Bioperfectus is pleased to announce that we have obtained CE Mark for our Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit (Self-test).